{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:43Z","timestamp":1786991143530,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T00:00:00Z","timestamp":1436486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jaad.2015.06.060","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T08:16:55Z","timestamp":1439021815000},"page":"645-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series"],"prefix":"10.1016","volume":"73","author":[{"given":"Vivian Y.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khiem","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forum","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Konia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell A.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reason","family":"Wilken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki Shirakawa","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Fitzmaurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta M.","family":"Monjazeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Burrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.jaad.2015.06.060_bib1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.060_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma\u2013a review of current and future treatment options","volume":"95","author":"Maverakis","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2015.06.060_bib3","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.jaad.2015.06.060_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jso.21968","article-title":"Intra-lesional interleukin-2 for the treatment of in-transit melanoma","volume":"104","author":"Boyd","year":"2011","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.060_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in\u00a0malignant melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br J Dermatol"},{"issue":"17","key":"10.1016\/j.jaad.2015.06.060_bib6","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.060_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0b013e328345e95e","article-title":"Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream","volume":"21","author":"Garcia","year":"2011","journal-title":"Melanoma Res"},{"issue":"11","key":"10.1016\/j.jaad.2015.06.060_bib8","article-title":"Detailed protocol for administration of intralesional IL-2 for the treatment of stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines","volume":"20","author":"Patel","year":"2014","journal-title":"Dermatol Online J"},{"issue":"9","key":"10.1016\/j.jaad.2015.06.060_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ejca.2004.01.037","article-title":"Tumor burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2","volume":"40","author":"Safwat","year":"2004","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.060_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2567.2003.01703.x","article-title":"Apoptosis induction by interleukin-2-activated cytotoxic lymphocytes in a squamous cell carcinoma cell line and Daudi cells\u2013involvement of reactive oxygen species-dependent cytochrome c and reactive oxygen species-independent apoptosis-inducing factors","volume":"110","author":"Yamamoto","year":"2003","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.060_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.060_bib12","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.4049\/jimmunol.173.5.3051","article-title":"Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod","volume":"173","author":"Palamara","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.060_bib13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions","volume":"148","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.060_bib14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2133.2008.08709.x","article-title":"Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1\/Th2 balance in patients with metastatic melanoma","volume":"159","author":"Green","year":"2008","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2015.06.060_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.2005.03.6830","article-title":"Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma","volume":"24","author":"Cesana","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215018666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215018666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:35:30Z","timestamp":1759271730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215018666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0190962215018666"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.06.060","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725713270.793511613","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.06.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}